• Winter Storm Watch - Click for Details
    ...WINTER STORM WATCH IN EFFECT FROM WEDNESDAY MORNING THROUGH LATE WEDNESDAY NIGHT...
    Effective: February 12, 2025 @ 6:00am
    Expires: February 13, 2025 @ 3:00am
    WHAT
    Heavy snow possible. Total snow accumulations between 6 and 8 inches possible.
    WHERE
    Portions of north central, northwest, and west central Illinois and east central, northeast, and southeast Iowa.
    WHEN
    From Wednesday morning through late Wednesday night.
    IMPACTS
    Travel could be very difficult. The hazardous conditions could impact the Wednesday morning and evening commutes.
    ADDITIONAL DETAILS
    North winds 10 to 15 mph, with gusts up 25 mph may cause some blowing and drifting snow, especially on east-west roads.
    PRECAUTIONARY/PREPAREDNESS ACTIONS
    Monitor the latest forecasts for updates on this situation.

AbbVie secures option to license Simcere’s blood cancer drug candidate

SHARE NOW

(Reuters) -AbbVie has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical’s unit for markets outside China, in a deal valued at up to $1.06 billion, the companies said on Monday.

The U.S. drugmaker will make upfront and milestone payments, and pay royalties on sales outside China, while it would receive royalties on sales within China.

The drug candidate, SIM0500, is currently undergoing early-stage clinical trials in both China and the U.S. in patients with relapsed or refractory multiple myeloma, a type of blood cancer.

AbbVie has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection last year.

The firm has bought neuroscience drug developer Cerevel Therapeutics, cancer drug developer ImmunoGen and Alzheimer’s therapy developer Aliada in 2024 through deals worth over $20 billion in total.

(Reporting by Aaditya Govind Rao in Bengaluru; Editing by Vijay Kishore)

Brought to you by www.srnnews.com

Submit a Comment